Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARalpha) in Non-Somatotroph Pituitary Tumours and the Effects of PPARalpha Agonists on MMQ cells
ROSTOMYAN, Liliya ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'endocrinologie clinique
Colapietro, A
Arcella, A
Ventura, L
Angelucci, A
Giangaspero, F
Esposito, V
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Jaffrain-Réa, ML
Language :
English
Title :
Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARalpha) in Non-Somatotroph Pituitary Tumours and the Effects of PPARalpha Agonists on MMQ cells
Daly A. F. Rixhon M. Adam C. Dempegioti A. Tichomirowa M. A. Beckers A. High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab: 2006; 91 4769 4775
Sumanasekera W. K. Tien E. S. Turpey R. Vanden Heuvel J. P. Perdew G. H. Evidence that peroxisome proliferator-activated receptor alpha is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2. J Biol Chem: 2003; 278 4467 4473
Beckers A. Aaltonen L. A. Daly A. F. Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev: 2013; 34 239 277
Rotondi S. Modarelli A. Oliva M. A. Rostomyan L. Sanita P. Ventura L. Daly A. F. Esposito V. Angelucci A. Arcella A. Giangaspero F. Beckers A. Jaffrain-Rea M. L. Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH 3 cells. Mol Cell Endocrinol: 2016; 426 61 72
König B. Rauer C. Rosenbaum S. Brandsch C. Eder K. Stangl G. I. Fasting upregulates PPARalpha target genes in brain and influences pituitary hormone expression in a PPARalpha dependent manner. PPAR Res: 2009; 181609
Tolón R. M. Castillo A. I. Aranda A. Activation of the prolactin gene by peroxisome proliferator-activated receptor-alpha appears to be DNA binding-independent. J Biol Chem: 1998; 273 26652 26661
Takeda M. Otsuka F. Otani H. Inagaki K. Miyoshi T. Suzuki J. Mimura Y. Ogura T. Makino H. Effects of peroxisome proliferator-activated receptor activation on gonadotropin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope LbetaT2 cells. J Endocrinol: 2007; 194 87 99
Kota B. P. Huang T. H. Roufogalis B. D. An overview on biological mechanisms of PPARs. Pharmacol Res: 2005; 51 85 94
Vitale S. G. Laganà A. S. Nigro A. La rosa V. L. Rossetti P. Rapisarda A. M. La Vignera S. Corrado F. Buscema M. D'Anna R. Peroxisome Proliferator-Activated Receptor modulation during metabolic diseases and cancers: Master and Minions. PPAR Res: 2016; 6517313
Derosa G. Sahebkar A. Maffioli P. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. J Cell Physiol: 2018; 233 153 161
Pollinger J. Merk D. Therapeutic applications of the versatile fatty acid mimetic WY14643. Expert Opin Ther Pat: 2017; 27 517 525
Heaney A. P. Fernando M. Melmed S. PPAR-gamma receptor ligands: Novel therapy for pituitary adenomas. J Clin Invest: 2003; 111 1381 1388
Bogazzi F. Ultimieri F. Raggi F. Russo D. Vanacore R. Guida C. Viacava P. Cecchetti D. Acerbi G. Brogioni S. Cosci C. Gasperi M. Bartalena L. Martino E. PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol: 2004; 150 863 875
Winczyk K. Pawlikowski M. Immunohistochemical detection of PPARgamma receptors in the human pituitary adenomas: Correlation with PCNA. Folia Histochem Cytobiol: 2005; 43 137 141
Pozzi A. Capdevila J. H. PPARalpha ligands as antitumorigenic and antiangiogenic agents. PPAR Res: 2008; 906542
Gao J. Yuan S. Jin J. Shi J. Hou Y. PPARα regulates tumor progression, foe or friend? Eur J Pharmacol: 2015; 15 560 564
Jaffrain-Rea M. L. Angelini M. Gargano D. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: Pathological and clinical implications. Endocr Relat Cancer: 2009; 16 1029 1043
Leontiou C. A. Gueorguiev M. van der Spuy J. Quinton R. Lolli F. Hassan S. Chahal H. S. Igreja S. C. Jordan S. Rowe J. Stolbrink M. Christian H. C. Wray J. Bishop-Bailey D. Berney D. M. Wass J. A. Popovic V. Ribeiro-Oliveira A. Jr. Gadelha M. R. Monson J. P. Akker S. A. Davis J. R. Clayton R. N. Yoshimoto K. Iwata T. Matsuno A. Eguchi K. Musat M. Flanagan D. Peters G. Bolger G. B. Chapple J. P. Frohman L. A. Grossman A. B. Korbonits M. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab: 2008; 93 2390 2401
Jaffrain-Rea M. L. Di Stefano D. Minniti Esposito V. Bultrini A. Ferretti E. Santoro A. Faticanti Scucchi L. Gulino A. Cantore G. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: Secreting versus non-secreting adenomas. Endocr Relat Cancer: 2002; 9 103 113
Vroonen L. Jaffrain-Rea M. L. Petrossians P. Tamagno G. Chanson P. Vilar L. Borson-Chazot F. Naves L. A. Brue T. Gatta B. Delemer B. Ciccarelli E. Beck-Peccoz P. Caron P. Daly A. F. Beckers A. Prolactinomas resistant to standard doses of cabergoline: A multicenter study of 92 patients. Eur J Endocrinol: 2012; 167 651 662
Fratticci A. Grieco F. A. Spilioti C. Giangaspero F. Ventura L. Esposito V. Piccirilli M. Santoro A. Gulino A. Cantore G. Alesse E. Jaffrain-Rea M. L. Differential expression of neurogenins and NeuroD1 in human pituitary tumors. J Endocrinol: 2007; 194 475 484
Greenman Y. Stern N. Non-functioning pituitary adenomas. Best Pract Res Clin Endocrinol Metab: 2009; 23 625 638
Nishioka H. Inoshita N. Mete O. Asa S. L. Hayashi K. Takeshita A. Fukuhara N. Yamaguchi-Okada M. Takeuchi Y. Yamada S. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol: 2015; 26 349 355
Caronti B. Palladini G. Calderaro C. Bevilacqua M. G. Petrangeli E. Esposito V. Tamburrano G. Gulino A. Jaffrain-Rea M. L. Effects of gonadal steroids on the growth of human pituitary adenomas in vitro. Tumour Biol: 1995; 16 353 364
Jaffrain-Rea M. L. Petrangeli E. Ortolani F. Fraioli B. Lise A. Esposito V. Spagnoli L. G. Tamburrano G. Frati L. Gulino A. Cellular receptors for sex steroids in human pituitary adenomas. J Endocrinol: 1996; 151 175 184
Colao A. Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol: 2011; 7 267 278
Blanquart C. Mansouri R. Fruchart J. C. Staels B. Glineur C. Different ways to regulate the PPARalpha stability. Biochem Biophys Res Commun: 2004; 319 663 670
Wadosky K. M. Willis M. S. The story so far: Post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation. Am J Physiol Heart Circ Physiol: 2012; 302 H515 H526
Hirotani M. Tsukamoto T. Bourdeaux J. Sadano H. Osumi T. Stabilization of peroxisome proliferator-activated receptor alpha by the ligand. Biochem Biophys Res Commun: 2001; 288 106 110
Hibberts N. A. Simpson D. J. Bicknell J. E. Broome J. C. Hoban P. R. Clayton R. N. Farrell W. E. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res: 1999; 5 2133 2139
Karavitaki N. Collison K. Halliday J. Byrne J. V. Price P. Cudip S. Wass J. A. What is the natural history of nonoperated nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf): 2007; 67 938 943
Oystese K. A. Evang J. A. Bollerslev J. Non-functioning pituitary adenomas: Growth and aggressiveness. Endocrine: 2016; 53 28 34
Featherstone K. White M. R. David J. S. The prolactin gene: A paradigm of tissue-specific gene regulation with complex temporal transcription dynamics. J Neuroendocrinol.: 2012; 24 977 990
Bernardes A. Souza P. C. Muniz J. R. Ricci C. G. Ayers S. D. Parekh N. M. Godoy A. S. Trivella D. B. Reinach P. Webb P. Skaf M. S. Polikarpov I. Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: A new mode of ligand recognition and receptor stabilization. J Mol Biol: 2013; 425 2878 2893
Shimomura K. Ikeda M. Ariyama Y. Proks P. Shimomura Y. Mori M. Matsumoto S. Effect of peroxisome proliferator-activated receptor alpha ligand fenofibrate on K(v) channels in the insulin-secreting cell line HIT-T15. Gen Physiol Biophys: 2006; 25 455 460
Gonzalez-Iglesias A. E. Murano T. Li S. Tomić M. Stojilkovic S. S. Dopamine inhibits basal Prolactin release in pituitary lactotrophs through pertussis toxin-sensitive and -insensitive signaling pathways. Endocrinology: 2008; 149 1470 1479
Merk D. Zettl M. Steinhilber D. Werz O. Schubert-Zsilavecz M. Pirinixic acids: Flexible fatty acid mimetics with various biological activities. Future Med Chem: 2015; 7 1597 1616
Pyper S. R. Viswakarma N. Yu S. Reddy J. K. PPARalpha: Energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal: 2010; 8 e002
Lakshmi S. P. Reddy A. T. Banno A. Reddy R. C. PPAR agonists for the prevention and treatment of lung cancer. PPAR Res: 2017; 8252796
Esmaeili M. A. Yadav S. Gupta R. K. Waggoner G. R. Deloach A. Calingasan N. Y. Beal M. F. Kiaei M. Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Hum Mol Genet: 2016; 25 317 332
